[Investigation on the adequate administration interval with OK-432, using the cytotoxicity test].
Tsukuda
M
M
Dept. of Head and Neck Surgery, Kanagawa Cancer Center.
Furukawa
S
S
Yoshida
T
T
Yanoma
S
S
Watanabe
A
A
Takahashi
K
K
Ono
T
T
Sawaki
S
S
D001688:Biological Products / Q000008:administration & dosage*; D003601:Cytotoxicity Tests, Immunologic; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D010610:Pharyngeal Neoplasms / Q000628:therapy*; D010844:Picibanil / Q000008:administration & dosage* / Q000627:therapeutic use
D001688:Biological Products; D010844:Picibanil